सिर और गर्दन का कैंसर
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
कहाँ जाना है
इस trial के लिए 6 hospitals इन इंडिया में patients ले रहे हैं।
रजिस्ट्री समरी (तकनीकी)
The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refractory/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). HNSCC is a type of cancer that develops in the head and neck regions, including the outer tissue layer of the mouth and throat. This study will focus on participants with HNSCC who are treatment-naive (have not received prior treatment) in the R/M setting.
स्पॉन्सर: Janssen Research & Development, LLC
ClinicalTrials.gov पर NCT07276399
रजिस्ट्री में आखिरी अपडेट 25 Sep 2026 · हमने 20 Oct 2026 को पढ़ा